Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicenter, Open Label, Clinical Trial of the Anti-PD1 Monoclonal Antibody Pembrolizumab (MK-3475) as Consolidation Therapy in Multiple Myeloma Patients With Residual Disease After Treatment

NCT02636010 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT02636010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02636010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicenter, Open Label, Clinical Trial of the Anti-PD1 Monoclonal Antibody Pembrolizumab (MK-3475) as Consolidation Therapy in Multiple Myeloma Patients With Residual Disease After Treatment
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2016
Completion date
February 20, 2020
Enrollment
20 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma